The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to severe" disease and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.
Hyderabad-based Optimus Pharma is one of the firms that had received DCGI's nod. It had stated on Tuesday that it would be launching its frontline COVID-19 medication Molnupiravir in the Indian market in a day or two.
Pharma major Sun Pharmaceutical Industries Limited today said that one of its wholly owned subsidiaries has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of MSD (a trade name of Merck & Co., USA) and Ridgeback’s molnupiravir under the brand name Molxvir in India for treatment of certain categories of adult patients with COVID-19.
When applying the drug benfooxythiamine, an inhibitor of this pathway, SARS-CoV-2 replication was suppressed and infected cells did not produce coronaviruses.